Chronic Obstructive Pulmonary Disease (COPD) Market Research and Analysis 2023 to 2033Posted by Ganesh Shinde on March 2nd, 2023  In 2023, the global Chronic Obstructive Pulmonary Disease (COPD) market is anticipated to be worth US$ 21.58 billion. With rising alcohol use, the global demand for Chronic Obstructive Pulmonary Disorder (COPD) is expected to expand at a CAGR of 4.4% between 2023 and 2033, totaling approximately US$ 33.19 billion by 2033. According to a study by the Global Burden of Disease (2016), performed by the Institute of Health Metrics and Evaluation, there are 251 million incidences of COPD globally. As per the World Health Organization, globally, approximately 200 million people were diagnosed with COPD in 2016. Moreover, rapid urbanization in developing countries in the Asia Pacific exposes the population to various forms of lung irritants that could be a major risk factor to cause COPD. Additionally, the World Health Organization (WHO) states that the most common cause of COPD is exposure to tobacco smoke both via first hand as well as second-hand smoking. This global increase in the prevalence of COPD is a major factor fueling the growth of the COPD market in the forthcoming years. In addition, the rise in consumption of tobacco among millennials, coupled with the rise in the awareness among population, regarding the use of generic drug are projected to contribute to the revenue share of the chronic obstructive pulmonary disease market in the near future. According to the Centre for Disease Control and Prevention (CDCP), the cost related to COPD in the US were 32.1 $ billion in 2010, and rose to 49 billion by 2020. Hence, the continual growth witnessed in the cases of COPD among population worldwide is a major factor that will intensify the growth of the COPD market over the forecast period. Competitive Landscape Prominent players in the Chronic Obstructive Pulmonary Disease (COPD) market are Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, and Verona Pharmaceuticals, among others. Browse More@ https://www.futuremarketinsights.com/reports/chronic-obstructive-pulmonary-disease-copd-market Key Segments Covered in the Chronic Obstructive Pulmonary Disease (COPD) Industry Analysis Chronic Obstructive Pulmonary Disease (COPD) Market by Drug Class:
Chronic Obstructive Pulmonary Disease (COPD) Market by Type:
Chronic Obstructive Pulmonary Disease (COPD) Market by Distribution Channel:
Like it? Share it! More by this author |